What changed
$RMD — WATCHLIST 📊
ResMed Inc.
🎯 Q2 2026 | Rev $1B | EPS $2.86 vs $2.80 🟢
💡 Market expects ongoing pressure from GLP-1 weight-loss drugs reducing sleep apnea prevalence; the recent beat may be seen as transitory. Our variant view is that the threat is overblown, but we lack a near-term catalyst to prove it, and the quant model expects flat 6m returns.
📉 Reward/Risk: 0.63:1
🏢 Business Quality: 7/10 - dominant market share, recurring mask/device revenue, high switching costs, but facing disruptive threat from GLP-1s and potential margin compression.
📊 Valuation: fair - trading at 18.2x trailing P/E, slightly below own 18.5x median, but near the low end of a narrow historical range.
🔮 Catalyst: Next quarterly earnings (est. June 2026)
💰 Entry: $188.425, stop $170, target $207
📊 Our read: WATCHLIST. Full analysis →
https://stockduty.xyz/s/RMD0622
Also in play: $ASML $LRCX $AMAT $KLAC $TER $SPLK